Abstract
Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic. Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.
Original language | English |
---|---|
Pages (from-to) | 312-317 |
Number of pages | 6 |
Journal | Sultan Qaboos University Medical Journal |
Volume | 10 |
Issue number | 3 |
Publication status | Published - Dec 2010 |
Externally published | Yes |
Keywords
- Hepatitis C virus
- Infection
- Interferon
- Liver
- MicroRNAs
- Therapy
ASJC Scopus subject areas
- Medicine(all)